{
    "id": 2070,
    "fullName": "RB1 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "RB1 loss indicates loss of the RB1 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5925,
        "geneSymbol": "RB1",
        "terms": [
            "RB1",
            "OSRC",
            "p105-Rb",
            "p110-RB1",
            "pp110",
            "PPP1R130",
            "pRb",
            "RB"
        ]
    },
    "variant": "loss",
    "createDate": "10/06/2014",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12573,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RB1 loss was associated with acquired resistance to Ibrance (palbociclib) in an estrogen-receptor positive breast cancer cell line in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 2007,
                "profileName": "RB1 loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1152,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sirolimus (rapamycin) slowed pituitary tumors and decreased the occurrence of thyroid tumors in Rb1+/- mice (PMID: 23454836).",
            "molecularProfile": {
                "id": 2007,
                "profileName": "RB1 loss"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 903,
                    "pubMedId": 23454836,
                    "title": "Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23454836"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6268,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RB1-deficient small cell lung cancer cell lines were resistant to Trilaciclib (G1T28) in culture and in xenograft models (PMID: 26826116).",
            "molecularProfile": {
                "id": 2007,
                "profileName": "RB1 loss"
            },
            "therapy": {
                "id": 3074,
                "therapyName": "Trilaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5519,
                    "pubMedId": 26826116,
                    "title": "Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26826116"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10295,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Trichostatin A (TSA) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).",
            "molecularProfile": {
                "id": 2007,
                "profileName": "RB1 loss"
            },
            "therapy": {
                "id": 2867,
                "therapyName": "Trichostatin A",
                "synonyms": null
            },
            "indication": {
                "id": 768,
                "name": "retinoblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8274,
                    "pubMedId": 18483379,
                    "title": "Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18483379"
                },
                {
                    "id": 8275,
                    "pubMedId": 23498719,
                    "title": "Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23498719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6269,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Trilaciclib (G1T28) and Hycamtin (topotecan) inhibited tumor growth in RB1-deficient small cell lung cancer cell line xenograft models, with greater efficacy than Hycamtin (topotecan) alone (PMID: 26826116).",
            "molecularProfile": {
                "id": 2007,
                "profileName": "RB1 loss"
            },
            "therapy": {
                "id": 4109,
                "therapyName": "Topotecan + Trilaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5519,
                    "pubMedId": 26826116,
                    "title": "Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26826116"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3904,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, the CDK4/6 inhibitor, Ibrance (palbociclib), was not effective in a variety of solid tumors with Rb1-deficiency (PMID: 26649278).",
            "molecularProfile": {
                "id": 2007,
                "profileName": "RB1 loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4276,
                    "pubMedId": 26649278,
                    "title": "CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26649278"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10297,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Entinostat (MS-275) inhibited growth of retinoblastoma cell lines in culture and inhibited tumor growth in a retinoblastoma cell line xenograft model (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).",
            "molecularProfile": {
                "id": 2007,
                "profileName": "RB1 loss"
            },
            "therapy": {
                "id": 1541,
                "therapyName": "Entinostat",
                "synonyms": null
            },
            "indication": {
                "id": 768,
                "name": "retinoblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8274,
                    "pubMedId": 18483379,
                    "title": "Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18483379"
                },
                {
                    "id": 8275,
                    "pubMedId": 23498719,
                    "title": "Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23498719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1153,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sirolimus (rapamycin) decreased tumor occurrence, tumor hypoxia and tumor vascularization in a retinoblastoma mouse model with functionally inactivated Rb protein (PMID: 21468343, PMID: 1689463).",
            "molecularProfile": {
                "id": 2007,
                "profileName": "RB1 loss"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 768,
                "name": "retinoblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 904,
                    "pubMedId": 21468343,
                    "title": "Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21468343"
                },
                {
                    "id": 905,
                    "pubMedId": 1689463,
                    "title": "Retinoblastoma in transgenic mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/1689463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10296,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zolinza (vorinostat) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).",
            "molecularProfile": {
                "id": 2007,
                "profileName": "RB1 loss"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 768,
                "name": "retinoblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8274,
                    "pubMedId": 18483379,
                    "title": "Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18483379"
                },
                {
                    "id": 8275,
                    "pubMedId": 23498719,
                    "title": "Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23498719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5863,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in triple-receptor negative breast cancer cell lines harboring PTEN and RB1 loss in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 21971,
                "profileName": "PTEN loss RB1 loss"
            },
            "therapy": {
                "id": 3956,
                "therapyName": "Palbociclib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5864,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Pictilisib (GDC-0941) induced growth inhibition in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 21971,
                "profileName": "PTEN loss RB1 loss"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5865,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 21971,
                "profileName": "PTEN loss RB1 loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8539,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 26352,
                "profileName": "BRAF mut RB1 loss"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8546,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 26352,
                "profileName": "BRAF mut RB1 loss"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8536,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531).",
            "molecularProfile": {
                "id": 26352,
                "profileName": "BRAF mut RB1 loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9603,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an acute lymphocytic leukemia cell line harboring BCR-ABL1 and loss of RB1 demonstrated decreased sensitivity to Ibrance (palbociclib) in culture (PMID: 26637365).",
            "molecularProfile": {
                "id": 26917,
                "profileName": "BCR - ABL1 RB1 loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7316,
                    "pubMedId": 26637365,
                    "title": "Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26637365"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer mouse cells expressing MYC T58A and loss of RB1 and TP53 demonstrated sensitivity to Alisertib (MLN8237) in culture, resulting in inhibition of cell growth (PMID: 28089889).",
            "molecularProfile": {
                "id": 27138,
                "profileName": "MYC T58A RB1 loss TP53 loss"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9856,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alisertib (MLN8237) enhanced the sensitivity of Platinol (cisplatin) combined with Vepesid (etoposide) in small cell lung cancer mouse models expressing MYC T58A and loss of TP53 and RB1, resulting in complete tumor growth inhibition, stable disease in 62.5% (10/16), and decreased tumor volume by 30% in three of the mice (PMID: 28089889).",
            "molecularProfile": {
                "id": 27138,
                "profileName": "MYC T58A RB1 loss TP53 loss"
            },
            "therapy": {
                "id": 5257,
                "therapyName": "Alisertib + Cisplatin + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer mouse cells expressing MYC T58A and loss of RB1 and TP53 demonstrated sensitivity to Barasertib (AZD1152) in culture, resulting in inhibition of cell growth (PMID: 28089889).",
            "molecularProfile": {
                "id": 27138,
                "profileName": "MYC T58A RB1 loss TP53 loss"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10045,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type NOTCH1 and loss of RB1 demonstrated resistance to Kisqali (ribociclib) in culture, resulting in limited inhibition of cell growth (PMID: 28151717).",
            "molecularProfile": {
                "id": 27230,
                "profileName": "NOTCH1 wild-type RB1 loss"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5602,
                "name": "T-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7921,
                    "pubMedId": 28151717,
                    "title": "Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2007,
            "profileName": "RB1 loss",
            "profileTreatmentApproaches": [
                {
                    "id": 4559,
                    "name": "HDAC Inhibitor",
                    "profileName": "RB1 loss"
                }
            ]
        },
        {
            "id": 21971,
            "profileName": "PTEN loss RB1 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21977,
            "profileName": "CCNE1 amp RB1 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26352,
            "profileName": "BRAF mut RB1 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26917,
            "profileName": "BCR - ABL1 RB1 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27138,
            "profileName": "MYC T58A RB1 loss TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27230,
            "profileName": "NOTCH1 wild-type RB1 loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}